Teladoc Health (NYSE:TDOC) Insider Fernando Rodrigues Sells 2,324 Shares

by · The Cerbat Gem

Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Fernando Rodrigues sold 2,324 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $17,406.76. Following the completion of the sale, the insider directly owned 4,209 shares of the company’s stock, valued at approximately $31,525.41. The trade was a 35.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded up $0.03 on Wednesday, reaching $7.53. 4,719,190 shares of the company’s stock were exchanged, compared to its average volume of 5,787,774. Teladoc Health, Inc. has a twelve month low of $6.35 and a twelve month high of $15.21. The company has a fifty day moving average of $8.02 and a 200-day moving average of $7.76. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -5.88 and a beta of 2.04. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71.

Teladoc Health (NYSE:TDOC – Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business had revenue of $626.44 million during the quarter, compared to the consensus estimate of $625.66 million. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. Teladoc Health’s revenue for the quarter was down 2.2% compared to the same quarter last year. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. On average, research analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Teladoc Health by 4.2% in the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after purchasing an additional 891,732 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Teladoc Health by 23.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after acquiring an additional 1,325,106 shares in the last quarter. Geode Capital Management LLC boosted its stake in Teladoc Health by 2.1% during the second quarter. Geode Capital Management LLC now owns 4,150,197 shares of the health services provider’s stock worth $36,153,000 after acquiring an additional 84,356 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Teladoc Health by 5.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,571,673 shares of the health services provider’s stock worth $20,471,000 after purchasing an additional 127,960 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Teladoc Health by 11.1% in the third quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after acquiring an additional 227,385 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Wall Street Analyst Weigh In

TDOC has been the topic of a number of research analyst reports. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Citigroup lifted their target price on Teladoc Health from $9.50 to $10.50 and gave the company a “neutral” rating in a research report on Tuesday, October 21st. Evercore ISI dropped their target price on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a report on Thursday, October 30th. Bank of America reduced their price target on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 25th. Finally, BMO Capital Markets assumed coverage on shares of Teladoc Health in a research report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.68.

Read Our Latest Research Report on TDOC

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Featured Articles